What is Curapel?
Curapel is a University of Manchester spin-out established in 2014, dedicated to creating patent-protected dermatological products for unmet clinical needs in conditions like eczema and psoriasis. The company's product line includes Pellamex, a dietary supplement for skin barrier function; Pelladerm, a topical cream for psoriasis; and Pellatone, an after-sun cream designed to reduce skin tone and inflammation. Curapel's focus is on providing safe, effective, and naturally derived solutions for individuals managing chronic skin issues.
How much funding has Curapel raised?
Curapel has raised a total of $507K across 1 funding round:
Private Equity
$507K
Private Equity (2016): $507K with participation from Lancaster Capital and Finance Wales
Key Investors in Curapel
Lancaster Capital
Lancaster Capital is a private fund that acts as a hub for private investors, focusing on making sound equity investments after substantial business success.
Finance Wales
Finance Wales, now part of the Development Bank of Wales, provides business finance solutions including loans and equity, supporting companies in Wales with a focus on economic growth and technology ventures.
What's next for Curapel?
The recent major strategic investment positions Curapel for accelerated growth and further product development. This enterprise-level backing suggests a transition into a scaling phase, likely enabling the company to expand its market reach, enhance its manufacturing capabilities, and potentially pursue further clinical validation for its existing portfolio. The strategic nature of the investment may also signal partnerships or collaborations aimed at broadening the application of Curapel's dermatological innovations.
See full Curapel company page
